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Abstract Tumor-inWltrating lymphocytes (TILs) have been
successfully used for adoptive cell transfer (ACT) immuno-
therapy; however, due to their scarce availability, this
therapy is possible for a limited fraction of cutaneous
melanoma patients. We assessed whether an eVective pro-
tocol for ex vivo T-cell expansion from peripheral blood
mononuclear cells (PBMCs), suitable for ACT of both
cutaneous and ocular melanoma patients, could be identi-
Wed. PBMCs from both cutaneous and ocular melanoma
patients were stimulated in vitro with autologous, irradiated
melanoma cells (mixed lymphocyte tumor cell culture;
MLTCs) in the presence of IL-2 and IL-15 followed by the
rapid expansion protocol (REP). The functional activity of
these T lymphocytes was characterized and compared with
that of TILs. In addition, the immune inWltration in vivo of
ocular melanoma lesions was analyzed. An eYcient in vitro
MLTC expansion of melanoma reactive T cells was
achieved from all PBMC’s samples obtained in 7 cutaneous
and ocular metastatic melanoma patients. Large numbers of
melanoma-speciWc T cells could be obtained when the
REP protocol was applied to these MLTCs. Most MLTCs
were enriched in non-terminally diVerentiated TEM cells
homogeneously expressing co-stimulatory molecules (e.g.,
NKG2D, CD28, CD134, CD137). A similar pattern of
anti-tumor activity, in association with a more variable expres-
sion of co-stimulatory molecules, was detected on short-term
in vitro cultured TILs isolated from the same patients. In
these ocular melanoma patients, we observed an immune
inWltrate with suppressive characteristics and a low rate of
ex vivo growing TILs (28.5% of our cases). Our MLTC
protocol overcomes this limitation, allowing the isolation
of T lymphocytes with eVector functions even in these
patients. Thus, anti-tumor circulating PBMC-derived T
cells could be eYciently isolated from melanoma patients
by our novel ex vivo enrichment protocol. This protocol
appears suitable for ACT studies of cutaneous and ocular
melanoma patients.
Keywords Cutaneous melanoma · Ocular melanoma · 
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Introduction
The incidence of melanoma has increased over the past
three decades [1]. In addition, this tumor is resistant to stan-
dard therapies with a life expectancy of less then 1 year for
metastatic melanoma patients [2]. Tough new targeted ther-
apies [3] and immunotherapy trials [4, 5], however, suggest
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improved in the near future. Ocular melanoma, though
infrequent, is a very aggressive disease with a dismal prog-
nosis since 50% of patients die from metastatic disease
[6, 7]. Notably, the biological and molecular proWles of ocular
melanoma showed relevant diVerences compared to cutane-
ous melanoma, with the Wrst type of tumor commonly
developing liver metastasis. For example, the mutated
BRAF, which is detected in up to 62% of cutaneous mela-
noma and represents a novel target molecule [3], is rarely
found in ocular melanoma [8]. Furthermore, the eye has
been considered an “immune privileged” site maintained by
a variety of immune suppressive mechanisms (e.g., TGF-,
IL-10, immune cells with negative regulatory functions)
that can sustain the development of ocular tumors [9].
However, immunogenic intraocular tumors leading to the
immune-mediated rejection have been documented in ani-
mal models [10–12]. It has been reported that the presence
of either tumor-inWltrating lymphocytes (TILs) or tumor-
inWltrating macrophages (TIMs) is associated with poor
prognosis in uveal melanoma patients [9]. Thus, it remains
to be ascertained if immune stimulation may favor or con-
trol the progression of ocular tumors. In fact, it has been
shown in cutaneous melanoma that tumor cells can produce
immuno-modulating factors, which exhaust or block the
immune response and recruit immune cells with negative
regulatory activity (T regulatory cells, Tregs; myeloid-
derived suppressor cells, MDSCs; suppressive macro-
phages, M2) to a speciWc site [13, 14]. Therefore, immuno-
therapeutic protocols that can modify and rescue anti-tumor
immune responses need to be designed for both cutaneous
and ocular melanoma patients.
DiVerent active strategies have been used to induce anti-
tumor immunity in cancer patients mainly based on the tar-
geting of a variety of tumor-associated antigens (TAAs) by
active therapy (vaccination) with peptide, protein or DNA/
RNA [15–17]. These vaccination strategies, while increas-
ing systemic anti-tumor immune responses, resulted in lim-
ited clinical outcome [16–18], though a recently performed
peptide-based phase II vaccination trial documented an
increase in the median overall survival in metastatic mela-
noma patients [5]. On the other hand, the adoptive T-cell
therapy (ACT) can overcome the suppressive tumor milieu
by using immune cells with cancer speciWcity grown out-
side of the patient and infused in large numbers following
pre-conditioning by chemotherapy, alone or in combination
with patient total body irradiation [19–21].
ACT with TILs isolated from metastatic melanoma
lesions led to objective tumor regression in 49–72% of
patients with many long-term sustained responses [20, 21].
However, TILs can be exploited for ACT studies only in
melanoma patients with resectable tumors and from which
T cells can be expanded ex vivo (approximately 60–70%)
[20, 22]. A recent published analysis identiWed the parame-
ters, such as age, sex and the type of systemic therapy, that
can negatively inXuence the ex vivo expansion of TILs
[22].
The persistence in vivo of the infused T cells was highly
associated with clinical responses. The in vivo eVectiveness
of TILs was also associated with the diVerentiation state of
the T cells, telomere length and CD27 expression, factors
that are relevant for speciWc anti-tumor activity [23–25]).
These results have been conWrmed in a phase II clinical
study showing high frequency of objective regressions in
metastatic melanoma patients [26].
An alternative approach has been explored for patients
without resectable lesions or with low number of TILs
using autologous lymphocytes isolated from the peripheral
blood genetically modiWed with genes encoding for anti-
tumor T-cell receptors (TCRs) [19, 27, 28]. These studies
showed encouraging clinical responses by using T-cell
receptor (TCR) speciWc for diVerentiating (Melan-A/
MART-1, CEA) or cancer testis (MAGE-A3, NY-ESO-1)
antigens, which could be applied to tumors having diVerent
histological origins [27]. This strategy however permits the
targeting of only a single tumor antigen by the engineered T
lymphocytes with the risk of tumor variants selection.
Further eVorts are therefore needed to develop ACT protocols,
which employ the use of T lymphocytes with the ability to
target a wider range of tumors and have a greater potential
of tumor site migration. This would result in treatment for a
larger number of cancer patients.
To this aim, we characterized anti-melanoma immune
responses of T cells isolated both from the peripheral blood
and from the TILs of cutaneous and ocular melanoma
patients. As a result, we identiWed a new protocol that
allows for the in vitro enrichment and expansion in large
scale of T lymphocytes obtained from PBMCs, which were
compared to those obtained with TILs. Furthermore, this
protocol beneWts from the stimulation with the autologous
tumor cells, which in turn leads to the selection of T cells
directed against multiple TAAs. Therefore, this protocol
would be suitable for ACT clinical studies in the vast
majority of both cutaneous and ocular melanoma patients
particularly when TILs are not available.
Materials and methods
Cell lines, PBMCs and TILs
Melanoma cell lines were established in vitro from surgi-
cally resectable tumor lesions from both cutaneous (#1061,
1067, 2710, 4478D, 49318, 0342, 25368 and 7 mel) and
ocular (#2130, 4330, 4022, 1141, 37165, 48409 and 15765)
melanoma patients. The informed consent was obtained123
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melanoma lines used for this study were JOFR-IA, DAJU
(kindly provided by Dr Pierre Coulie, de Duve Institute,
Université Catholique de Louvain, Brussels, Belgium), 501
mel, a gift of Dr. Paul F. Robbins, (National Cancer Insti-
tute, NIH, Bethesda, MD) and the 15392 line provided by
Dr. Chiara Castelli (Istituto Nazionale Tumori, Milan,
Italy). These melanoma lines were cultured in RPMI 1640
(Biowittaker, Lonza, Treviglio, Italy) supplemented with
10% FBS (Lonza), 20 mM HEPES, penicillin (200 U/ml),
streptomycin (200 ug/ml) and 2 mM Glutamax (Invitrogen,
Carlsbad, CA).
Melanoma cell lines used for the stimulation in vitro of
autologous PBMCs were maintained in 48-h cultures with
RPMI plus 10% human serum (HS).
Other cell lines used were the lymphoblastoid cell line
T2 and HLA-A3-C1R, the erythroblastoid cell lines K562
(American Type Cell Culture, ATCC-LGC, LGC Stan-
dards) and the EBV-B cell line 1869 [29].
PBMCs were obtained by Ficoll density gradient centri-
fugation (Ficoll-Paque PLUS, GE Healthcare Bio-Science
Ab, Uppsala, Sweden) of peripheral blood drawn from both
ocular and cutaneous melanoma patients, while TILs were
isolated from melanoma lesions. The MHC class I and II
typing of PBMCs of melanoma patients was performed by
sequence-speciWc oligonucleotide PCR.
Immunohistochemistry
Surgical specimens from ocular melanoma patients
(N = 10 primary uveal melanoma) were Wxed in formalin
and embedded in paraYn. Immunohistochemistry (IHC)
analysis was done on 5-m tissue sections, and the stain-
ing was performed with a sensitive non-biotin detection
system (Novo Link polymer, Novacastra) and with diam-
inobenzidine or double stain with diaminobenzidine and
alkaline phosphatase-fast red development. Heat-induced
antigen retrieval was done with Tris–EDTA (pH 9.0) in
water bath for 30 min. The monoclonal antibodies (mAbs)
used were directed against the following antigens: anti-
CD3, anti-CD4, anti-CD25 and anti-CD163 (Novocastra),
anti-CD8 (DB Biotech), anti-FOXP3 (CNIO Madrid),
anti-GATA3 (Becton–Dickinson; BD Biosciences, San
Jose, CA, USA) and anti-T-Bet (Santa Cruz Biotechnol-
ogy, Inc.). Staining was carried out by an automatic
immunostainer (Autostainer 480, ThermoWsher), and
immunostained slides were digitalized with the Aperio
(Aperio Technologies, Vista, CA, USA) slide scanner and
corresponding 1 mm2 of tumor areas on serial sections
was selected. Immunolabeled cells were counted and
expressed as percentage on total cells obtained using the
IHC Nuclear Image Analysis algorithm of the Spectrum
Plus software (Aperio).
Flow cytometry analysis
The HLA class I and II expression by melanoma cell lines
was measured by Xow cytometry using anti-HLA-A2,
HLA-ABC and HLA-DR mAbs conjugated with Xuores-
cein isothiocyanate (FITC), phycoerytrin (PE) and peridi-
nin chlorophyll protein (PerCP)-Cy-5.5 (BD Biosciences),
respectively. For melanoma line immuno-phenotyping, the
following mAbs were used: anti-MICA, anti-MICB and
anti-ULBP1-4 (provided by Amgen, Thousand Oaks, CA,
USA), anti-MAGE 57B (provided by Dr. Giulio Spagnoli,
University of Basel, Switzerland), anti-NY-ESO-1 E978
(Zymed Laboratories, San Francisco, CA, USA), anti-Sur-
vivin (SVV) 8E2 (Thermo Fisher ScientiWc), anti-Melan-A/
MART-1 M2-7C10, anti-gp100 HMB45 and anti-IL13Ra2
B-D13 (Santa Cruz Biotechnology) and the polyclonal Ab
anti-COA-1 (Protein Expert; Marseille, France). The goat
anti-mouse IgG PE conjugated or the goat anti-rabbit IgG
FITC (Dako Italia SpA, Milan, Italy) was used as second-
ary Abs.
Phenotypic characterization of T-cell cultures was done
by the multiparametric Xow cytometry analysis using the
following mAbs: TCR/, CD4, CD62L, CD57 and IFN-
FITC conjugated; TCR/, CCR7, CD127, CD107a and
perforin PE conjugated; NKG2D, CD27, CD56 and CD137
allophycocyanin (APC) conjugated; CD8 and CD16 APC-
H7 conjugated; CD25 APC-Cy7 conjugated; CD134 PE-
Cy5 conjugated; CD45RO PE-Cy7 conjugated; CD45RA
PE Texas Red (ECD) conjugated; CD28 PerCpCy5.5 and
CD3 PaciWc Blue (PB) conjugated (BD Biosciences).
Lymphocytes were incubated with mAbs to surface
markers at 4°C for 30 min, washed with PBS 5% FBS
buVer and Wxed with 0.5% paraformaldehyde. Intracellular
staining was performed using BD CytoWx/Cytoperm
Fixation/Permeabilization Solution Kit (BD Bioscience
Pharmingen). Data were acquired on the LSRII Xow cytome-
ter (BD) and analyzed with FCS Express Software (Denovo
Software, Los Angeles, CA, USA) or Kaluza Software
(Beckman Coulter, Brea, CA, USA). Results are expressed
as MRFI, representing the ratio between the mean Xuores-
cence intensity of cells stained with the selected mAb and
that of cells stained with isotype-matched control mouse
immunoglobulins or, in the case of multiparametric pheno-
type analysis, as the percentage of positive cells subtracted
above background.
Mixed lymphocytes tumor cell culture (MLTC)
PBMCs isolated from melanoma patients were thawed and
incubated overnight at 37°C. PBMCs (106 cells/well) were
cultured in the presence of autologous irradiated (150 Gy)
melanoma cells at a lymphocyte to tumor ratio of 5:1 in 24-
well plates with X-VIVO15 and 5% HS. DiVerent cytokine123
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the most suitable in vitro culture conditions in terms of T
lymphocyte expansion and eYciency in tumor cell recogni-
tion: (1) 120 IU/ml rhIL-2 (Proleukin, Novartis Farma,
Origgio, Italy); (2) 120 IU/ml rhIL-2 and 10 ng/ml rhIL-15
(Peprotech, Rocky Hill, NJ, USA); (3) 10 ng/ml rhIL-15;
(4) 5 ng/ml rh-IL-7 (Peprotech); (5) 120 IU/ml rhIL-2 and
5 ng/ml rhIL-7; (6) 120 IU/ml rhIL-2 and 10 ng/ml rhIL-21
(Peprotech); (7) 10 ng/ml rhIL-21 alone. Fresh medium
containing the above indicated cytokines was replaced
every 3 days. These MLTCs were stimulated weekly with
irradiated autologous melanoma cells, and their reactivity
was tested starting from the 3rd week of culture.
ELISPOT assay
To determine the speciWc recognition of tumor cells by T
lymphocytes, the ELISPOT assay was performed as previ-
ously described [30]. Anti-human IFN- mAb (1-D1 K),
the secondary biotinylated anti-IFN- mAb (7-B6-1) and
the secondary alkalin phosphatase-streptavidin were pur-
chased from Mabtech (Naka Stand, Sweden). The speciWc-
ity of T-cell recognition was determined by the inhibition
of the IFN- release after pre-incubation of target cells with
the W6/32 (anti-HLA class I) or L243 (anti-HLA class II
DR molecules) mAbs (ATCC). In addition, T lymphocytes
were pre-treated with the anti-NKG2D mAb (clone M585,
kindly provided by Amgen) before the incubation with tar-
get cells. T lymphocytes incubated with phytohemaggluti-
nin (PHA) and concanavalin-A (ConA) (Sigma-Aldrich)
were used as a positive control for IFN- secretion. The
cell lines T2 (HLA-2+), 1869 EBV-B (HLA-A3+ and A24+)
and C1R (HLA-A3 +) were used as antigen-presenting
cells and pulsed with 10 g/ml of Melan-A/MART-1-,
gp100-, MAGE-A2- and A3-, NY-ESO-1- or SVV-HLA-A2-
restricted peptides (JPT Peptide technologies, Berlin,
Germany) or MAGE-A1-, gp100- and COA-1-HLA-A3-
restricted peptides [29, 30]. In addition, HLA-A3-C1R cells
transiently transfected by electroporation with expression
vectors (pcDNA3) coding for COA-1 and SVV antigens
were used as target cells as well.
Statistical analysis of the diVerences between means in
the cytokine release assays was performed using two-tailed
t test (P < 0.05).
In vitro rapid expansion of T lymphocytes
The rapid expansion of TILs or of MLTC-derived T cells
was performed using the rapid expansion protocol (REP) as
previously described by Dudley et al. [31]. BrieXy, T lym-
phocytes were cultured in T25 Xasks in X-VIVO15, 5% HS
and in the presence of 200-fold excess of irradiated (50 Gy)
feeder cells that were isolated and pooled from three
healthy donors. On day 4, 30 ng/ml of anti-CD3 (OKT-3,
Ortho Clinical Diagnostics, Rochester, USA) mAb and
6,000 U/ml of rh-IL-2 were added. The culture media con-
taining rh-IL-2 was replaced every 3 days. At day 14 fol-
lowing the in vitro expansion, the speciWc reactivity by T
lymphocytes against autologous and/or HLA-matched allo-
geneic melanoma lines and melanoma-associated epitopes
was determined by IFN- release assay (ELISPOT) as
described above.
Assessment of the cytotoxic activity
The cytotoxic activity of T lymphocytes was determined by
the CD107a mobilization assay [32] and intracellular detec-
tion of perforin. T lymphocytes were co-cultured with
autologous or allogeneic HLA-matched tumor cells at a 4:1
ratio in polystyrene tubes. Control tubes contained lympho-
cytes alone or co-cultured with HLA-mismatched mela-
noma cells. Positive controls were comprised of cells
stimulated with PHA/Con-A or OKT3. CD107a-PE (BD
Pharmingen) mAb was added to the T-cell cultures. After
1 h of incubation at 37°C, 1 l/tube monesin (Golgi-Stop,
BD Bioscience) was added as per kit protocol to the cul-
tures then incubated at 37°C for an additional 3 or 5 h. At
the end of the incubation, time cells were stained for the
surface markers CD3 and CD8, permeabilized and stained
with anti-perforin PE and/or anti-IFN- FITC mAbs (BD
Pharmingen). Samples were then analyzed by Xow cytometry
as described above.
Results
Comparison of the eYciency of diVerent cytokines 
in the isolation and in vitro expansion of anti-melanoma 
T lymphocytes
To isolate in vitro anti-melanoma T cells, mixed lymphocyte
tumor cell cultures (MLTCs) were set up by stimulating
PBMCs from melanoma patients with irradiated autologous
melanoma cells. Initially, the eYcacy of diVerent cytokines,
alone or in combination, on the in vitro growth of T lympho-
cytes was compared. To this aim, independent MLTCs from
the cutaneous melanoma patient #2710 were set up in the
presence of the following cytokines: (1) rhIL-2; (2) rhIL-2
and rhIL-15; (3) rhIL-15; (4) rh-IL-7; (5) rhIL-2 and rhIL-7;
(6) rhIL-2 and rhIL-21; and (7) rhIL-21. At day 21, the high-
est expansion rate of lymphocytes (105-fold increase of the
T-cell number) was obtained with IL-2 alone (Fig. 1).
EYcient expansion in vitro of T cells was also obtained by
culturing the MLTCs with IL-2 and IL-15 (87.5-fold
increase) or with IL-2 + IL-7 (68.4-fold increase) (Fig. 1).
Interestingly, similar increases in the number of T cells were123
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followed for the second week of culture with IL-2 plus IL-7
(data not shown). The MLTC grown either with IL-2 plus
IL-21 or with IL-15 alone led to a lower expansion of T cells
(35.88 and 13.5-fold increase, respectively) (Fig. 1). No pro-
liferation of T cells was observed in the presence of IL-21
alone (Fig. 1).
To assess the reactivity of these MLTCs against tumor
cells, IFN- release was determined by ELISPOT. As
shown by the representative data in Fig. 2, T lymphocytes
maintained in culture with IL-2 and IL-15 released the
highest amount of IFN- (n. 337 spots/5,000 cells) after the
incubation with the autologous tumor cells (#2710 mel)
(Fig. 2b) compared to the other in vitro culture conditions
(n. 38.5–199 spots/5,000 cells) of MLTCs (Fig. 2a, c, d).
SpeciWc inhibition of IFN- release was observed after pre-
incubation of the autologous tumor cells with the anti-HLA
class I mAb (W6/32), not with the anti-HLA class II (L243)
mAb (Fig. 2b). Similarly, the recognition of the HLA-
matched (HLA-A*0201) allogeneic cutaneous melanoma
line 501 mel was superior (n. 371 spots/5,000 cells; Fig. 2b)
by culturing T cells with IL-2 plus IL-15 compared to the
others cytokines or their combinations (20–205 n. spot/
5,000 cells; Fig. 2a, c, d). Moreover, all the MLTCs (Fig. 2)
failed to recognize the HLA-mismatched allogeneic cutane-
ous melanoma 15392 mel. No signiWcant reactivity against
the K562 line was detected for the MLTCs cultured with
IL-2 plus IL-15 or IL-2 plus IL-21 (Fig. 2b, d), while IFN-
release, though at low levels (22 and 42 spots/5,000 cells,
respectively), occurred following the incubation of the
MLTCs cultured with IL-2 alone or IL-2 plus Il-7 with this
cell line (Fig. 2a, c). Higher reactivity (195 spots/5,000
cells) against the K562 cell line as compared with the autol-
ogous melanoma (62 spots/5,000 cells) was observed by
lymphocytes expanded in vitro with IL-15 alone, indicating
that an enrichment of NK-type immune responses occurred
in this MLTC (data not shown). Thus, IL-2 plus IL-15 led
to the most eYcient isolation and expansion in vitro of mel-
anoma-speciWc T lymphocytes, and therefore, this cytokine
combination was utilized for the subsequent ex vivo selec-
tion of anti-tumor T lymphocytes.
IdentiWcation of a new protocol to isolate in vitro 
T lymphocytes with speciWc reactivity against 
the autologous tumor
The MLTC-based protocol has been applied to activate and
expand in vitro circulating T cells from cutaneous mela-
noma patients.
Independent MLTC cultures were set up from PBMCs
isolated from 6 metastatic cutaneous melanoma patients
(#2710, 4478D, JOFR-IA, DAJU, 0342 and 7). T cells were
stimulated weekly with irradiated autologous tumor cells in
the presence of IL-2 and IL-15. Following the two rounds
of in vitro stimulation (day 15), the tumor speciWcity of
these MLTCs was assessed by IFN- release (ELISPOT
assay). Representative data of patients #2710 are shown in
Fig. 3a. In addition, results of patient #4478D are shown in
Fig. 1S Panel A of the supplementary online data. These T
lymphocytes exhibit speciWc recognition of the autologous
tumor lines (285 spots/5,000 cells for #2710 Fig. 3a) with
signiWcant inhibition (53%; P · 0.001) of cytokine release
after pre-treatment of target cells with the W6/32 mAb.
Instead, low inhibition (26% for #2710) of IFN- release
was found in the presence of the anti-MHC class II (L243)
mAb (Fig. 3a).
Notably, the MLTC from the HLA-A*0201+ melanoma
patient #2710 speciWcally (92% of inhibition in the
presence of the W6/32 mAb) recognized the HLA class
I-matched allogeneic 501 mel line and the HLA-A*0201-
restricted Melan-A/MART-1-derived epitope (Fig. 3a). The
evidence that the recognition of the Melan-A/MART-1-
derived epitope by this MLTC was weaker than the autolo-
gous and the allogeneic 501 mel tumor lines (121 vs. 285
and 272 N. spots/5,000 cells, respectively; Fig. 3a) suggests
that these T lymphocytes can exhibit speciWc recognition of
a broad panel of TAAs expressed by tumor cells. On the
contrary, no recognition of a panel of HLA-A1-restricted
peptides (MAG3-A1, MAGE-A3 and COA-1) was
observed for the MLTC of patient #4478D (data not
shown). In fact, only for patient #0342, the MLTC-derived
T lymphocytes recognized the HLA-A1-restricted MAGE-
A3 antigen (data not shown). Thus, this protocol allowed
to isolate in vitro MLTCs from 6 out of 6 cutaneous
melanoma patients with speciWc reactivity against the
Fig. 1 Expansion in vitro of T lymphocytes cultured with diVerent
cytokines or their combinations. PBMCs (1 £ 106 cells) isolated from
the cutaneous melanoma patient 2710 were stimulated in vitro with
irradiated autologous tumor cells at 1:5 tumor cell lymphocyte ratio in
the presence of cytokines indicated in the Wgure. Fresh medium was re-
placed every 3 days. T-cell growth was assessed at days 9, 14 and 21.
Results represent averages of triplicates of the fold increase number
with SD · 10%; statistical analysis of diVerences between means of
fold of increase of T-cell numbers was performed by two-tailed t test
(P · 0.01)123
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neic HLA-matched tumor lines (e.g., 2710, 0342 and DAJU
mel). Most of these T lymphocyte cultures recognized a
broad array of TAAs, probably including also unknown
antigens, since only in limited cases (#2710, 0342), the rec-
ognition of molecularly deWned epitopes was observed. The
speciWcity of anti-tumor reactivity by the isolated MLTCs
was corroborated by the lack of the reactivity of HLA-
mismatched melanoma lines (49318 mel in Fig. 3a) and of
the NK target line K562.
We were able to establish in vitro primary uveal mela-
noma lines with eYciencies approaching 57% (N = 8 tumor
cell lines out 12 primary and 2 metastatic ocular tumor
samples). Albeit lower than those obtainable for cutaneous
melanoma (72%), it is still higher than expected. We found
that the immune proWle of these ocular melanoma cell lines
was similar to that of cutaneous melanoma counterparts as
described in the supplements and Tables 1S and 2S (avail-
able online). Thus, we investigated whether our MLTC pro-
tocol could also be applied to ocular melanoma patients.
As shown by the representative data for MLTCs 2 in
Fig. 3b, these T-cell cultures exerted speciWc recognition of
the autologous 15765 mel line (236 spots/5,000 cells) with
53% of inhibition with the anti-MHC class I mAbs (W6/32)
(Fig. 3b). We could also isolate CD4+ T cells speciWcally
directed against the autologous tumor (#15765) as shown
by the inhibition of IFN- release by L243 mAb in MLTC1
(Figure 1S Panel B of supplementary results). These data
indicate a preferential CD4+ and CD8+ T-cell enrichment in
MLTC 1 and 2, respectively, as conWrmed by the pheno-
type analysis (61 and 82% of positive cells, respectively;
data not shown). The inhibition of autologous tumor reac-
tivity by CD8+ T lymphocytes (MLTC 2, Fig. 3b) was
increased in the presence of both anti-MHC class I and anti-
NKG2D mAbs (53 vs. 69% of inhibition) with W6/32 and
W6/32 + anti-NKG2D mAbs, respectively), suggesting that
the speciWc recognition of the ocular melanoma cells
occurred by the engagement of both TCR and NKG2D as
observed for cutaneous melanoma (Fig. 3b). No reactivity
directed to known TAAs (Gp100, MAGE-A1 and COA-1)
associated with the HLA-A3 molecules expressed by the
autologous cells from patient 15765 was detected.
Interestingly, we also observed that these T lympho-
cytes exhibited cytotoxic activity, measured by CD107a
Fig. 2 Tumor-speciWc recognition of MLTCs from patient #2710 cul-
tured in vitro in the presence of diVerent cytokines or of their combi-
nations. The speciWc tumor recognition of lymphocytes isolated from
PBMCs of the cutaneous melanoma patient 2710 and cultured for
2 weeks in the presence of diVerent cytokines was analyzed for IFN-
release (ELISPOT assay). IFN- secretion by T cells was assessed fol-
lowing the incubation with the autologous melanoma line (#2710 mel)
pre-treated or not with anti-HLA class I (W6/32) or anti-HLA class II
(L243) mAbs. The recognition of the allogeneic HLA-matched (HLA-
A*0201+ 501 mel) or HLA-mismatched (15392 mel) melanoma lines
and of the NK target cell line K562 was also determined. PHA/Con-A
was used as a positive control for IFN- release. Statistical analysis of
diVerences between means of IFN- released by T cells was done by
two-tailed t test (P · 0.01)123
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with that of IFN- production directed to the autologous
melanoma line (Fig. 4).
These results thus indicate that our MLTC protocol can
successfully isolate circulating T cells inducing speciWc
recognition of autologous tumor cells from both cutaneous
(N = 6) and ocular melanoma patients (N = 1).
Phenotype proWle of MLTC-derived T cells
The phenotype analysis of T lymphocytes following
MLTCs from the 6 cutaneous melanoma patients showed a
common enrichment of CD3+CD8+CD45RO+ (44–95% of
positive cells) with CD4+ T cells also detectable in the
range of 25–51% of positive cells (4478D, JOFR, 0342, 7
mel) (representative results from #2710 patient are shown
Fig. 5). These Wndings are in agreement with the evidence
that most of tumor recognition activity is HLA class
I-restricted (Figs. 3 and 1S). These T-cell cultures expressed,
though to a variable extent (20–40% of positive cells),
some co-stimulatory receptors such as CD28, NKG2D,
OX40 (CD134), 4-1BB (CD137), while CD27 was found
positive only in 3/6 patients (4478D, JOFR-IA and DAJU;
representative data are shown in Fig. 5). In addition, CCR7
and CD62L were mostly expressed at low levels, and
CD57 was not found on these MLTCs (data not shown).
Fig. 3 Isolation of highly tumor reactive T lymphocytes by the MLTC
protocol from cutaneous and ocular melanoma patients. PBMC from
#2710 cutaneous and #15765 ocular melanoma patients were stimu-
lated in vitro with irradiated autologous tumor cells at 1:5 tumor cell
lymphocyte ratio in the presence of IL-2 + IL-15. Following 2 weekly
stimulations, the tumor speciWcity of T cells was assessed by measur-
ing IFN- secretion (ELISPOT assay) after the incubation with the
autologous melanoma cells (#2710 and #15765, a, b, respectively) pre-
treated or not with anti-HLA class I (W6/32) or anti-HLA class II
(L243) mAbs. Moreover, T cells were also pre-incubated or not with
the anti-NKG2D mAb. The recognition of the allogeneic HLA-
matched (HLA-A*0201+ 501 mel, a) or HLA-mismatched (#49318
mel, a) melanoma line and of the NK target cell line K562 was also
determined. For patient #2710, the recognition of HLA-A2-restricted
TAA-isolated epitopes (Melan-A/MART-1, Panel A and Gp100,
SVV-1, COA-1, MAGE-A3, Tyr, data not shown) loaded onto T2 cells
was assessed. PHA/Con-A was used as a positive control for IFN-
release. Statistical analysis of diVerences between means of IFN-
released by T cells was done by two-tailed t test (P · 0.01)
Fig. 4 Cytotoxic activity of the MLTC isolated from the ocular mela-
noma patient 15765. The cytotoxic activity against the autologous tu-
mor by the MLTCs from patient 15765 was assessed as CD107a
mobilization and the production of perforin and IFN- (evaluated by
immunoXuorescence and cytoXuorimetric analysis) by CD8+ T cells (a
logical gate was used to identify CD8+ T cells) following the incuba-
tion with the autologous melanoma line (b, c) or allogeneic HLA-mis-
matched melanoma lines (501 and 2710 mel; data not shown). OKT3
stimulation of T cells was used as a positive control (data not shown).
Data are expressed as % of positive cells and represent averages of
duplicates with SD · 10%123
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in agreement with the phenotype of non-terminally diVer-
entiated eVector memory (TEM) (CD57-negative) T lym-
phocytes [33, 34]. Interestingly, T lymphocytes expressing
high levels of co-stimulatory molecules have previously
manifested potentially eYcient melanoma-speciWc reactiv-
ity and in vivo persistence [24, 25].
No T regulatory (Tregs) cells as identiWed by speciWc
staining for CD4+CD25highCD127dim were found in MLTCs
(data not shown).
Of note, a similar phenotype proWle was detected for
both the MLTC 1 and the MLTC 2 T cells of the ocular
melanoma patient 15765 (data not shown).
Thus, non-terminally diVerentiated anti-tumor TEM cells
could be ex vivo isolated by applying our protocol to circu-
lating lymphocytes.
Isolation and phenotypic characterization of TILs 
from cutaneous and ocular melanoma patients
The most encouraging results of ACT protocols for meta-
static melanoma patients have been obtained by the use of
TILs [20, 21]. Thus, we have carried out a comparison of
the phenotype and functional activity between MLTCs
and TILs, from both cutaneous and ocular melanoma
patients.
Initially, we isolated TILs from 5 metastatic cutaneous
melanoma (3 subcutaneous lesions #4478D, 9476, 25368
and 2 lymph node lesions #3681 and 4931, respectively)
and from 4 ocular melanoma (3 primary #3470, 1141,
4022 and one metastatic #15765) patients. The pheno-
type analysis of the T lymphocytes is shown in Fig. 6 (cuta-
neous melanoma patients # 3681, 4931, 9476 and 25368,
panels A, B and C and primary ocular melanoma patients
#3470, 1141 and 4022, panels D, E and F). TILs were cul-
tured in vitro for 5–7 days with 600 IU/ml of rh-IL-2 in
order to enrich T cells and to remove tumor cell contami-
nations. These TILs from melanoma were CD8+ T cells
(46–64% of positive cells), with 18–60% of CD4+ T cells
(Fig. 6a, d). Only TILs 9476 were enriched for CD4+ T
cells (94% of positive T cells; panel A). Higher levels of
CD8+ T cells (57–80% of positive cells), with the exception
of patient #1141 (98% of CD4+ T cells; Fig. 6d), were
found in TILs deriving from ocular melanoma lesions. All
T cells expressed homogeneously CD45RO (data not
shown) and high levels of CD28 (40–94% of positive
cells; Panels B and E), while CD27 was detected only in
TILs from two cutaneous melanoma patients (#25368 and
#9476, 39 and 46% of CD8+ T cells, respectively; panel B)
and in CD8+ lymphocytes from one ocular melanoma
patient (# 3470, 24% of CD8+ T cells; panel E). CD137
was detected at high levels in T cells from 2 out of 4
Fig. 5 Phenotype analysis of MLTCs. The phenotype analysis of T
lymphocytes isolated in vitro by MLTC before and after REP was as-
sessed by multiparametric IF and cytoXuorimetric analysis (see
“Materials and methods”). mAbs directed to the following molecules
were used: CD3, CD4, CD8, CD45RO, CD45RA, CCR7, CD62L,
NKG2D, CD27, CD28, OX40, 41BB, CD25, CD127, CD16, CD56
and CD57. Representative data of T cells (pre-REP MLTC) analysis
of patient #JOFR-IA are represented in the Figure (CD4 vs. CD8 a;
CD8 vs. NKG2D, b; CD8 vs. CD27, c; CD8 vs. CD28, Panel d; CD8
vs CD137, e; CD8 vs. CD134, f). Data are expressed as percentage of
positive cells123
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metastatic lesions #3681 and 4931), in the primary uveal mela-
noma #4022 (30% of CD8+ cells) (Fig. 6c, f, respectively)
and homogeneously in the metastatic ocular melanoma
patient #15765 (CD137 was also present in 100% of both
CD4+ and CD8+ cells; data not shown). Of note, 10–22% of
CD134+ T cells were detected in ocular melanoma  TILs
(both CD4 and CD8 T cells) and, to a lower extent (10–
12% of positive cells), in cutaneous melanoma deriving T
cells (Fig. 6c, f). CD134 was homogeneously associated
with both CD4+ and CD8+ T cells from TILs of #9476 and
#1141 cutaneous and ocular melanoma patients, respec-
tively (Fig. 6c, f). In addition, for all the patients, CD8+ T
cells expressed homogenously NKG2D (50–87% of posi-
tive cells) (data not shown). CD57 was detected to a vari-
able extent (11–23% of positive cells) in subpopulations
of both CD4+ and CD8+ T cells, indicating that most of
TILs were not terminally diVerentiated. No Tregs were
found in short-term cultured TILs of all the analyzed cuta-
neous and ocular melanoma patients (data not shown).
Therefore, TILs displayed an eVector memory non-termi-
nally diVerentiated phenotype, and in most cases, lower
levels of the expression of co-stimulatory molecules were
detected as compared with MLTC-derived T cells (see
Figs. 5, 6).
In vivo analysis of the immune inWltrate in ocular 
melanoma patients
Notably, an immune inWltrate was detected also by IHC
analysis in 10 primary ocular melanoma lesions (repre-
sentative results of patients #50306324 and 50316250 are
shown in the Fig. 6g–n and Figure 2S of Supplementary
results). In 6/10 tissues, CD4+ T cells were detected
(21–70 cells/1 mm2); Fig. 6h), while CD8+ enrichment in
ocular melanoma tissues was found only in three patients
(40–80 cells/1 mm2; Fig. 6m). In addition, heterogeneous
levels of Tbet and GATA3 (transcription factors associ-
ated with TH1 and TH2 type immune responses, respec-
tively) were observed (Figure 2S Panel B, C and F and G).
Interestingly, the presence of Tregs (evaluated as
CD25+FoxP3+) was found in association with the enrich-
ment of CD4+ T cells and with low inWltration of CD8+
lymphocytes (Fig. 6i, n). High numbers of macrophages
with suppressive activity were also observed as shown by
the staining with anti-CD163 mAb (Figure 2S Panels D
and H).
We found that TILs can be detected in primary ocular
melanoma lesions, though mostly CD4+ and in association
with the presence of Tregs and M2 macrophage, envision-
ing an immune inWltration possibly dominated by TH2 and/
or immune suppressive activity.
Functional characterization of TILs isolated 
from cutaneous and ocular melanoma patients
The short-term in vitro culture of TILs can, in most cases,
rescue their TH1 activity, as suggested by the phenotype
analysis (Fig. 6a–f and 2S Panels A–H). To prove this
hypothesis, we assessed—when the autologous tumor line
was available—the anti-melanoma activity by measuring
the IFN- release (ELISPOT) of TILs from ocular mela-
noma and compared to that of cutaneous melanoma.
Figure 7 shows representative results of TILs from the cuta-
neous melanoma #4478D (Panel A) and from the ocular
melanoma #15765 (Panel B) patients. High levels of IFN-
release (355 and 334 spots/5,000 cells for patients #4478D
and #15765, respectively) were observed following incuba-
tion of TILs from both patients with the autologous tumor
cell lines. Moreover, the tumor recognition was HLA-
restricted as the cytokine secretion was inhibited (65 and
58% for patients #4478D and #15765, respectively) by the
incubation of tumor cells with the anti-HLA-class I (W6/
32) mAb, but not by the anti-HLA class II mAb (L243). In
addition, both TIL cultures failed to recognize the alloge-
neic HLA-mismatched melanoma lines (1067 and 15392
lines; Fig. 7). Furthermore, lack of recognition of HLA-A3-
restricted TAA-derived epitopes (such as Gp100, MAGE-
A1 and COA-1) was observed for TILs as well as for
MLTC isolated from the 15765 patients (data not shown),
thus indicating that these T cells can recognize TAAs spe-
ciWcally associated with ocular melanoma.
These results demonstrate that the short-term in vitro
culture of TILs from ocular melanoma can rescue their TH1
activity and that anti-tumor TILs can be isolated from both
cutaneous and ocular melanoma patients.
Large number of anti-melanoma T lymphocytes 
can be eYciently isolated in vitro by REP of MLTCs
The REP protocol was applied to both MLTC and TILs iso-
lated from 10 cutaneous and ocular melanoma patients in
order to determine whether comparable expansion in vitro
of eVector T cells could be obtained. The results shown in
Fig. 8 indicate that eYcient expansion (68–148 £ 106 T
cells) of TILs (#15765 and #4478D) and MLTCs (#4478D,
#2710 and #0342) could be achieved with an increase value
of 240–592 times (Fig. 8, insert). Notably, similar expan-
sion of T lymphocytes was observed in TILs vs MLTCs of
the same patient (#4478D) (240 and 272 times number,
respectively) (insert of Fig. 8). Moreover, an eYcient
expansion of TILs from the ocular melanoma patient
#15765 was achieved (8.4 £ 107 cells starting from
1.5 £ 105 cells with an increase of 560 times) as well, thus
indicating that the possible anergic state of T cells isolated123
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vivo and such lymphocytes eYciently expanded.
The speciWc anti-tumor reactivity by MLTC-derived T
lymphocytes expanded in vitro in large scale with the use of
the REP protocol [31] was obtained for all of the 7 cutane-
ous or ocular melanoma patients (# 7, 2710, 0342, 4478D,
DAJU-1A, JOFR and 15765). Representative results of
patients 4478D and DAJU are shown in Figure 3S Panels A
and B, respectively, of supplementary online results). Simi-
lar results were obtained for the TILs isolated from three
patients (# 4478D, 25368 and 15765) following the appli-
cation of the REP as shown by the representative results in
Figure 4S of Supplementary (available online). In addition,
both MLTC- and TIL-derived T cells following the applica-
tion of REP maintained their phenotype observed prior to
the large scale expansion (data not shown).
In conclusion, our results indicate that, similarly to TILs
that have been thus far largely used for ACT studies [20],
Fig. 6 Characterization TILs isolated from both cutaneous and ocular
melanoma patients. TILs isolated by the mechanical processing of
surgically resected tumor lesions (N = 4 metastatic cutaneous mela-
noma and N = 3 primary ocular melanoma patients) were cultured for
5–7 days in X-Vivo-15 plus 5% HS and 600 IU/ml of rh-IL-2 in order
to enrich T cells and to remove tumor cell contaminations. IF and
cytoXuorimetric analysis was carried out according the procedures
indicated in “Materials and methods”. mAb directed to the following
molecules were used: CD3, CD4, CD8, CD45RO, CD45RA, CCR7,
CD62L, NKG2D, CD27, CD28, OX40, 41BB, CD25, CD127, CD16,
CD56, CD57. Representative results of CD4, CD8, CD27, CD28,
CD134 and CD137 are shown. Data are expressed as percentage of
positive cells (a–f). IHC analysis of the immune inWltration in ocular
melanoma patients was carried out (g–n). CD4 (brown staining)/CD8
(red staining) (h, m) and FOXP3 (brown)/CD25 (red) (i, n) in two oc-
ular melanoma tissues (# 050306324–0503161250). Hematoxylin/
eosin staining is shown in g, l). The scale bars represent 100 m.
MagniWcation £10123
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by REP can lead to the isolation of large numbers of eVec-
tor T cells. This protocol appears then to be suitable for
ACT clinical applications for cutaneous and, for the Wrst
time, for ocular melanoma patients.
Discussion
ACT represents a promising therapeutic approach for meta-
static melanoma. In fact, the infusion in metastatic patients
of autologous TILs has led to signiWcant responses in a high
number of clinical cases [20, 21]. A multicenter conWrma-
tory trial has been proposed to show that this complex tech-
nique of ex vivo expansion of TILs can be applied by
multiple institutions [35]. In addition, a simpliWed protocol
for the isolation and the growth in vitro of TILs has been set
up to improve both the eYciency of isolation of these T
lymphocytes and their anti-tumor potential for ACT studies
[26, 36]. Nevertheless, some features such as age, sex,
tumor location and any prior systemic therapy of patients
can aVect the success in TIL isolation [22]. Therefore, we
sought to identify an alternatively protocol, when TILs are
not available, which involves the isolation of polyclonal
anti-melanoma T lymphocytes from the PBMCs of both
cutaneous and ocular melanoma patients. We have success-
fully and reproducibly (7/7 patients) isolated anti-tumor cir-
culating T cells by the stimulation in vitro of PBMCs with
irradiated autologous tumor cells (MLTCs; Fig. 3 and also
Figure 1S of supplementary online data). The MLTCs cul-
tures isolated in vitro corresponded to non-terminally
diVerentiated TEM [33, 34] expressing high levels of co-
stimulatory molecules, a subpopulation of T cells that can
exhibit eYcient melanoma-speciWc reactivity and in vivo
persistence [24, 25].
In few cases (2/6), we could also molecularly identify
the TAAs (Melan-A/MART-1 and MAGE-A3) recognized
by the tumor-speciWc MLTC T cells. Nevertheless, the
cytokine release in the presence of the autologous tumor
recognition was higher compared to the TAA-directed reac-
tivity, suggesting that our protocol can achieve an ex vivo
enrichment of T lymphocytes reacting to multiple TAAs,
thus avoiding the selection of tumor immune variants.
Along this line, it has been documented that TILs, reactive
Fig. 7 Functional activity of TILs isolated from cutaneous and ocular
melanoma patients. TILs isolated from the mechanical processing
of surgically resected tumor lesions were cultured for 5–7 days in
X-Vivo-15 plus 5% HS and 600 IU/ml of rh-IL-2 in order to enrich T
cells and to remove tumor cell contaminations. The tumor recognition
of these TILs was assessed by measuring IFN- release (ELISPOT as-
say) after the incubation with the autologous melanoma cells (the cuta-
neous melanoma #4478D mel and the ocular melanoma #15765 mel,
a, b, respectively) pre-treated or not with anti-HLA class I (W6/32) or
anti-HLA class II (L243) mAbs. The recognition of the allogeneic
HLA-mismatched (1067 mel, a) or of the allogeneic HLA-matched
(HLA-A3+ 15392 mel, b) melanoma lines and of the NK target cell line
K562 was also determined. PHA/Con-A was used as a positive control
for IFN- release. Statistical analysis of diVerences between means of
IFN- released by T cells was done by two-tailed t test (P · 0.01)
Fig. 8 EYciency of expansion in vitro of anti-tumor T cells from both
MLTCs and TILs. T cells from MLTCs or TILs of cutaneous and
ocular melanoma patients were stimulated in vitro by REP in the pres-
ence of irradiated (50 Gy) allogeneic PBMCs from 3 healthy donors
plus OKT3 (30 ng/ml), and at day 4, 6,000 IU/ml of rh-IL-2 was add-
ed. Fresh medium with 6,000 IU/ml of rh-IL-2 was replaced every
3 days. After 15 days of in vitro culture, the growth of T cells was
evaluated. Data are represented as cell number and are the mean of
three independent experiments with SD · 10%. In the insert, the fold
increase number of these T-cell cultures is indicated123
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patients can be successfully exploited for ACT [20, 37, 38],
possibly targeting the heterogeneity of tumor cells.
Very little information is available on the immune-medi-
ated control of ocular melanoma [10, 11], and in addition,
this aggressive disease has limited therapeutic options [7,
8]. Therefore, immunotherapy-based treatment, as ACT,
can represent a promising approach for the control of this
disease. Interestingly, the application of our MLTC-based
protocol has led to the isolation ex vivo of tumor reactive T
cells from one ocular metastatic melanoma patient (Fig. 3
and Figure 1S of supplementary data). In addition, the phe-
notype of these T cells was of TEM type with the expression
of high level of co-stimulatory molecules, similarly to
MLTCs from cutaneous melanoma patients (data not
shown and Fig. 5). Of note, these T cells, in addition to
IFN- secretion (Figs. 3 and 1S), exerted cytotoxic activity
(Figs. 4) against the autologous tumor cells. Similar data
were obtained for cutaneous melanoma-derived MLTCs
(data not shown). Ocular melanoma is a rare disease, and
therefore, the availability of tumor cell lines and PBMCs in
an autologous setting is limited. However, our encouraging
results demonstrate a potential future wider exploitation of
our protocol that can be of beneWt also for these melanoma
patients. Since we could not molecularly identify the TAAs
recognized by the anti-ocular melanoma MLTC cultures,
we will further characterize these immune responses
exploiting T cells as probes for the molecular cloning of the
target molecule.
In order to determine whether our MLTC-derived
immune responses could be exploited for ACT protocols,
we have compared their anti-tumor activity and phenotype
with those of TILs. We have isolated TILs from both cuta-
neous (N = 5) and ocular (N = 4) melanoma patients and
found that they speciWcally exerted autologous tumor rec-
ognition (representative data are shown in Fig. 7). The phe-
notype analysis showed that non-terminally diVerentiated
TEM can be isolated from both TILs and MLTCs. However,
higher levels of co-stimulatory molecules were found in
MLTC lymphocytes, suggesting that eYcient anti-tumor
activity and persistence in vivo can be associated with
MLTCs rather than with TILs.
By IHC, we also analyzed the presence in vivo of the
immune inWltrate in 10 ocular melanoma surgical samples,
where we could detect TILs in 9/10 tissues, mostly CD4+T
cells (6/10 tissues). Only 3 cases showed high numbers of
CD8+ lymphocytes. We found an heterogeneous expression
of TH1 and TH2 type T cells, while the detection of CD25+
and FOXP3+ Treg cells was directly associated with high
level of CD4. Moreover, in all of the analyzed samples (10/
10), high levels of CD163+ macrophages were observed.
The presence of these cells in tumor tissues has been
described to be correlated with poor prognosis and with
suppressive immune functions [39, 40]. Therefore, our
observations indicate that ocular melanoma potentially rep-
resent an immune suppressive environment, in accord with
previous published data [9, 10], and similarly to cutaneous
melanoma [13, 14]. However, the ex vivo short-term cul-
ture of TILs can rescue their anti-tumor activity (Fig. 7).
Thus far, with our protocol based on the ex vivo enrichment
of circulating T cells (MLTCs), we have demonstrated that
we can overcome the anergic state of T cells induced by the
tumor milieu.
We obtained a remarkable high frequency of both long-
term (perpetual) and short-term (1–4 months) cell lines in
72 and 57% cutaneous and ocular melanoma, respectively.
A low rate of TILs isolation (38%) was observed from our
cutaneous melanoma patients as compared to the previous
published results (60–70%) [20, 22]. This diVerence may
depend on the limited population size we have analyzed
and/or on the small dimensions (0.5–1.5 cm diameter) of
the tumor fragments we have received. In ocular mela-
noma, there are no documented studies involving the isola-
tion of TILs on a large patient base. Nevertheless, we were
able to isolate and successfully culture TILs in 28.5% of
our patients. Thus, our data indicate that the application of
the MLTC method, which is based on tumor cell availabil-
ity, can be of interest since it is applicable to a large number
of melanoma patients from whom TILs cannot be obtained
and, in addition, to ocular melanoma subjects for whom
few studies documenting TIL isolation and characterization
are available [9, 12].
Notably, the REP stimulation [31] applied to the in vitro
isolated MLTCs indeed led to the successful expansion of
these T cells (Fig. 8). The Wnal number of T cells obtained
from MLTCs was comparable to that of TILs (Fig. 8);
moreover, we also demonstrated that after the REP, these T
lymphocytes retained their initial speciWc anti-tumor activ-
ity (Figure 3S of supplementary data available online).
Thus, we identiWed a new protocol that allows the isolation
of large number (2–10 billions) of T lymphocytes to be
infused in melanoma patients.
Durable clinical responses have been recently docu-
mented in stage IV melanoma patients infused with poly-
clonal anti-tumor PBMCs, pre-stimulated in vitro with the
autologous tumor cells, and given in combination with low-
dose IFN- [41]. This indicates that by the exploitation of
the immunogenicity of tumor cells, it is possible to
eYciently isolate and direct systemic anti-tumor immune
responses against the residual tumor cells.
A limitation of our approach is the availability of autolo-
gous tumor cells, although as we have shown above
(Figs. 3 and 1S of supplementary results) that short-term
cultured melanoma cells can be used. Alternatively, to
overcome the lack of autologous tumor cell lines, HLA-
matched/-semimatched allogeneic melanoma lines could be123
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have been selected ex vivo by the usage of allogeneic tumor
cells as stimulators [42].
Altogether, we have carried out a detailed characteriza-
tion of immune responses of T cells from the peripheral
blood vs tumor tissues of both cutaneous and ocular mela-
noma patients that allowed us identifying a novel MLTC-
based protocol to isolate and successfully expand ex vivo
polyclonal anti-tumor circulating T cells. In addition, our
protocol can overcome the possible anergic state of TILs
due to the immunesuppressive tumor environment. We
envision that our method may be suitable for ACT proto-
cols, when TILs are not available, for both cutaneous and
ocular melanoma patients.
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